Will Moderna Soar on Nov. 6?

Moderna stock has surged over 100% this year, driven by positive results from its personalized cancer vaccine candidate in combination with Merck's Keytruda. The company is scheduled to report Q3 earnings on Nov. 6, with investors focused on oncology progress and cancer vaccine development. While recent data leak caused a stock dip, the author expects the next major catalyst to come from fresh cancer vaccine data rather than the earnings report itself.